

## Orphan Drug Development Guidebook

### Building Block J305

This document defines the content of the Building Block created for each identified tool, incentives, initiative or practice introduced by public bodies or used by developers to expedite drug development in Rare Diseases (RDs).

ITEM	DESCRIPTION						
Building Block (BB) Title	Consultations on Pharmacogenomics / Biomarkers (As part of PMDA consultations)						
References	<ul style="list-style-type: none"> <li>• PMDA Website: Record of Consultations on Pharmacogenomics / Biomarkers               <ul style="list-style-type: none"> <li>– <a href="https://www.pmda.go.jp/english/review-services/consultations/0001.html">https://www.pmda.go.jp/english/review-services/consultations/0001.html</a></li> </ul> </li> <li>• PMDA Website: Record of Consultations on Pharmacogenomics / Biomarkers (Japanese)               <ul style="list-style-type: none"> <li>– <a href="https://www.pmda.go.jp/review-services/f2f-pre/consultations/0033.html">https://www.pmda.go.jp/review-services/f2f-pre/consultations/0033.html</a></li> </ul> </li> <li>• PMDA Website: User Fees               <ul style="list-style-type: none"> <li>– <a href="https://www.pmda.go.jp/review-services/drug-reviews/user-fees/0001.html">https://www.pmda.go.jp/review-services/drug-reviews/user-fees/0001.html</a> (Information of consultation fees, Japanese)</li> </ul> </li> </ul>						
Description	<p>Consultations on Pharmacogenomics / Biomarkers is one of the PMDA consultations. The purpose of this consultation is to provide general scientific advice for utilization of pharmacogenomics or biomarkers that are not specified in a certain product.</p> <p>The table of consultation fees is shown below.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Categories of Consultations</th> <th style="text-align: right;">User Fees (yen)</th> </tr> </thead> <tbody> <tr> <td>Elibility Evaluation</td> <td style="text-align: right;">3,270,600</td> </tr> <tr> <td>Key points of study/trial protocols</td> <td style="text-align: right;">1,199,900</td> </tr> </tbody> </table>	Categories of Consultations	User Fees (yen)	Elibility Evaluation	3,270,600	Key points of study/trial protocols	1,199,900
Categories of Consultations	User Fees (yen)						
Elibility Evaluation	3,270,600						
Key points of study/trial protocols	1,199,900						

ITEM	DESCRIPTION		
	Additional consultation for Eligibility Evaluation	995,700	
	Additional consultation for Key points of study/trial protocols plan	435,300	
Category	Regulatory Building Block		
Geographical scope	Japan		
Availability	Similar as for the PMDA consultations BB, this BB is available for developers within Japan for rare and non-rare diseases regardless of the applicant's nature (i.e., public/no-profit/academia, SME, etc)		
Scope of use	The purpose of this consultation is to provide general scientific advice for utilization of pharmacogenomics or biomarkers that is not specified in a certain product.		
Stakeholders	<ul style="list-style-type: none"> <li>• Drug/Medical device/Regenerative Medical Product developers</li> <li>• PMDA</li> </ul>		
Enablers/ Requirements	N/A		
Output	Scientific advice with meeting minutes from PMDA		
Best time to apply and time window	Anytime during medical product development. It takes approximately 24 weeks from application to receiving minutes.		
Expert tips	<p>PROs: Provision from PMDA for appropriate pharmacogenomics or biomarkers utilization in the development of a drug/medical device/regenerative medical product is obtained.</p> <p>CONs: N/A</p>		